ArticleInternational journal of women's health2025
Risk of Ovarian Metastasis and Prognosis in Patients with Neuroendocrine Carcinoma of the Uterine Cervix: A Multi-Center Retrospective Cohort Study.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine the risk of ovarian metastasis and prognosis in patients with neuroendocrine carcinoma of the uterine cervix (NECC). Methods: A retrospective review was conducted of the clinical and pathological information of patients with stage IA2 to IIA2 cervical cancer who underwent radical hysterectomy between 2008 and 2023. Multivariate Cox proportional hazards regression models were used to identify independent prognostic factors for the 5-year overall survival (OS) and disease-free survival (DFS). Results: The study included 1351 patients from four Chinese medical institutions. Compared to those with squamous carcinoma or adenocarcinoma, patients with NECC had a significantly higher risk of lymph vascular space invasion (LVSI) and more frequently received adjuvant radiotherapy. The overall rates of fallopian tube and ovarian metastases were low (< 1.0%). Furthermore, the ovary had a higher rate of metastasis than the fallopian tube (P< 0.001). Remarkably, none of the 75 patients with NECC exhibited fallopian tube or ovarian metastasis. The 5-year DFS and OS were significantly shorter in patients with NECC than in those with squamous carcinoma (5-year DFS, 64.7% vs 90.1%, P < 0.001; 5-year OS, 75.7% vs 89.6%, P < 0.001) or adenocarcinoma (5-year DFS, 64.7% vs 83.4%, P < 0.001; 5-year OS, 75.7% vs 88.7%, P=0.004). Multivariate analysis identified NECC as an independent risk factor for decreased 5-year DFS (aHR, 6.274; 95% CI, 3.749-10.499) and 5-year OS (aHR, 5.925; 95% CI, 3.097-11.336). Sensitivity assessments yielded consistent results. Conclusion: NECC is an independent risk factor associated with a worse prognosis. However, the rates of fallopian tube and ovarian metastases are low in NECC patients, suggesting that ovarian preservation may be a safe and feasible option for these patients. Further validation in broader, diverse populations is warranted to generalize these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.